What is claimed is:

1. A recombinant *Listeria* strain comprising a minigene nucleic acid construct~~, said construct~~ comprising an open reading frame encoding a chimeric protein, wherein ~~said~~ the chimeric protein comprises:

(a~~.~~) ~~-~~a bacterial secretion signal sequence~~, ~~;

(b~~.~~) a ubiquitin ~~(Ub)~~ protein~~, ~~; and

(c~~.~~) ~~-~~a peptide,

wherein ~~said~~ the bacterial secretion signal sequence, ~~said~~ the ubiquitin protein, and ~~said~~the peptide in (a~~.~~) to (c~~.~~) are ~~respectively~~ arranged ~~in tandem~~ from the amino-terminus to the carboxy-terminus of the chimeric protein.

2. The recombinant *Listeria* strain of claim 1, wherein ~~said~~the ~~*Listeria* further comprises two or more~~ open reading frame~~s~~ encoding the chimeric protein is linked to a second open reading frame ~~linked~~ by a Shine-Dalgarno ribosome binding site nucleic acid sequence, wherein the second open reading frame encodes a second chimeric protein comprising: (a) a second bacterial secretion signal sequence; (b) a second ubiquitin protein; and (c) a second peptide, wherein the second bacterial secretion signal sequence, the second ubiquitin protein, and the second peptide in (a) to (c) are arranged from the amino terminus to the carboxy terminus of the second chimeric protein.

3. The recombinant *Listeria* ~~of any one of claims 1-2, wherein said *Listeria* further comprises one to four open reading frames linked by a Shine-Dalgarno ribosome binding site nucleic acid sequence between~~strain of claim 2, wherein each open reading frame encodes a different peptide.

4. The recombinant *Listeria* strain of any one of claims 1-3, wherein ~~said~~the peptide comprises one or more neoepitopes.

~~5. The recombinant *Listeria* of any one of claims 1-4, wherein each open reading frame comprises a different peptide.~~

~~6~~5. The recombinant *Listeria* strain of any one of claims 1-~~4~~5, wherein ~~said~~the minigene nucleic acid construct further comprises a 5' bacterial promoter driving expression of the minigene nucleic acid construct.

~~7~~6. The recombinant *Listeria* strain of claim ~~6~~5, wherein ~~said~~the 5' bacterial promoter is an *actA* promoter, an *hly* promoter, or a *p60* promoter.

~~8~~7. The recombinant *Listeria* strain of any one of claims 1-~~6~~7, wherein ~~said~~the bacterial secretion signal sequence ~~encodes~~ comprises an $ActA_{100}$ signal sequence comprising the first 100 amino acids of ~~the~~ an ActA protein signal sequence.

~~9~~8. The recombinant *Listeria* strain of any one of claims 1-~~7~~8, wherein ~~said~~the bacterial secretion signal sequence is a secretion signal sequence from a listeriolysin O (LLO) protein ~~comprising SEQ ID NO: 4~~.

~~10~~9. The recombinant *Listeria* strain of any one of claims 1-~~9~~8, wherein ~~said~~the recombinant *Listeria* strain comprises ~~a~~ genomic mutations or deletions in ~~the~~ a D-alanine race~~s~~mase (*dal*) gene and ~~the~~ a D-amino acid transferase (*dat*) gene~~s~~.

~~11~~10. The recombinant *Listeria* strain of claim ~~10~~9, wherein the recombinant *Listeria* strain further comprises a nucleic acid molecule comprising ~~first~~ an open reading frame encoding a metabolic enzyme, and wherein ~~said~~the metabolic enzyme complements ~~said~~the ~~*dal*/*dat*~~ genomic mutations or deletions in the *dal* gene and the *dat* gene.

~~12. The recombinant *Listeria* of claim 11, wherein said nucleic acid molecule is integrated into the *Listeria* genome.~~

~~13~~11. The recombinant *Listeria* strain of claim ~~11~~10, wherein ~~said~~the nucleic acid molecule is in a plasmid in ~~said~~the recombinant *Listeria* strain, and wherein ~~said~~the plasmid is stably maintained in ~~said~~the recombinant *Listeria* strain in the absence of antibiotic selection.

~~14~~12. The recombinant *Listeria* strain ~~of any one~~ of claims ~~11-13~~10 or 11, wherein ~~said~~the metabolic enzyme is an alanine racemase enzyme or a D-amino acid transferase enzyme.

~~15~~13. The recombinant *Listeria* strain of any one of claims ~~11-14~~10-12, wherein ~~said~~the minigene nucleic acid construct is integrated into the *Listeria* genome or is in an extrachromosomal plasmid in ~~said~~the recombinant *Listeria* strain.

~~16~~14. The recombinant *Listeria* strain of any one of claims 1-~~15~~13, wherein ~~said~~the recombinant *Listeria* strain comprises a genomic mutation or deletion in the *actA* gene.

~~17~~15. The recombinant *Listeria* strain of any one of claims 1-~~16~~14, wherein ~~said~~the recombinant *Listeria* strain comprises a genomic mutation or deletion in the *inlB* gene.

~~18~~16. The recombinant *Listeria* strain of any one of claims 1-~~17~~15, wherein ~~said~~the recombinant *Listeria* strain comprises a genomic mutation or deletion in the *prfA* gene.

~~19~~17. The recombinant *Listeria* strain of any one of claims 1-~~18~~16, wherein ~~said~~the recombinant ~~attenuated~~ *Listeria* strain is a *Listeria monocytogenes*.

~~20. A pharmaceutical composition comprising the recombinant *Listeria* of any one of claims 1-19, and a pharmaceutically acceptable carrier.~~

~~21. A method of eliciting an anti-tumor or anti-cancer response in a subject having a tumor or cancer, said method comprising the step of administering to said subject a recombinant *Listeria* comprising a minigene nucleic acid construct, said construct comprising an open reading frame encoding a chimeric protein, wherein said chimeric protein comprises:~~

~~a. a bacterial secretion signal sequence,~~

~~b. a ubiquitin (Ub) protein,~~

~~c. a peptide,~~

~~wherein said signal sequence, said ubiquitin and said peptide in a.-c. are respectively arranged in tandem from the amino-terminus to the carboxy-terminus, thereby enhancing an anti-tumor response in said subject.~~

~~22. The method of claim 21, wherein said *Listeria* further comprises two or more open reading frames linked by a Shine-Dalgarno ribosome binding site nucleic acid sequence.~~

~~23. The method of claim 21, wherein said *Listeria* further comprises one to four open reading frames linked by a Shine-Dalgarno ribosome binding site nucleic acid sequence between each open reading frame.~~

~~24. The method of claims 21-23, wherein said peptide comprises one or more neoepitopes.~~

~~25. The method of claims 21-24, wherein each open reading frame comprises a different peptide.~~

~~26. The method of claims 20-25, wherein said minigene construct further comprises a 5' bacterial promoter driving expression of the nucleic acid construct.~~

~~27. The method of claim 26, wherein said promoter is an *actA* promoter, an *hly* promoter, or a *p60* promoter.~~

~~28. The method of claims 21-27, wherein said bacterial secretion signal sequence encodes an ActA$_{100}$ signal sequence comprising the first 100 amino acids of the ActA protein signal sequence.~~

~~29. The method of claims 21-28, wherein said bacterial secretion signal sequence is a secretion signal sequence from listeriolysin O (LLO) protein.~~

~~30~~18. The ~~method of any one of claims 21-29, wherein said~~ recombinant *Listeria* ~~comprises a genomic mutation in the~~strain of claim 1, wherein the bacterial secretion signal sequence is a secretion signal sequence from a listeriolysin O (LLO) protein and comprises SEQ ID NO: 4, wherein the recombinant *Listeria* strain comprises genomic mutations or deletions in a D-alanine racemase (*dal*) gene, ~~and the~~ a D-amino acid transferase (*dat*) gene~~s.~~

~~31. The method of claim 30~~, and an *actA* gene, wherein ~~said~~the recombinant *Listeria* strain further comprises a nucleic acid molecule comprising ~~a first~~an open reading frame encoding a metabolic enzyme, and wherein ~~said~~the metabolic enzyme ~~complements an endogenous gene that is mutated or deleted in the chromosome of said recombinant *Listeria* strain.~~

~~32. The method of claim 33, wherein said nucleic acid molecule is integrated into the *Listeria* genome.~~

~~33. The method of claim 33, wherein said nucleic acid molecule is in a plasmid in said recombinant *Listeria* strain, and wherein said plasmid is stably maintained in said recombinant *Listeria* strain in the absence of antibiotic selection.~~

~~34. The method of any one of claims 31-33, wherein said metabolic enzyme~~ is an alanine racemase enzyme or a D-amino acid transferase enzyme.

19. A pharmaceutical composition comprising the recombinant Listeria strain of any one of claims 1-18, and a pharmaceutically acceptable carrier.

~~35. The method of any one of claims 21-34, wherein said minigene construct is integrated into the *Listeria* genome or is in an extrachromosomal plasmid in said *Listeria*.~~

~~36. The method of any one of claims 21-35, wherein said recombinant *Listeria* comprises a genomic mutation or deletion in the *actA* gene.~~

~~37. The method of any one of claims 21-36, wherein said recombinant *Listeria* comprises a genomic mutation or deletion in the *inlB* gene.~~

~~38. The method of any one of claims 21-37, wherein said recombinant *Listeria* comprises a genomic mutation or deletion in the *prfA* gene.~~

~~39. The method of any one of claims 21-38, wherein said recombinant attenuated *Listeria* is a *Listeria monocytogenes*.~~

~~40. The method of any one of claims 21-39, further comprising administration of an independent adjuvant.~~

~~41. The method of claim 40, wherein said adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSF) protein, a nucleotide molecule encoding a GM-CSF protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide.~~

~~42. The method of any one of claims 21-41, wherein said cancer comprises a lymphoma, a leukemia, a breast cancer, colorectal cancer, Head and neck squamous carcinoma, renal cell carcinoma, Pancreatic ductal adenocarcinoma, osteosarcoma, gastric cancer, non-small cell lung cancer or a bone cancer.~~

~~43. The method of any one of claims 21-42, wherein said cancer is a refractory cancer.~~

~~44. The method of claim 42, wherein said lymphoma is Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma.~~

~~45. The method of claim42, wherein said lymphoma is multiple myeloma.~~

~~46~~20. ~~A method of treating a tumor or cancer in a subject, said method comprising the step of administering to said subject~~Use of a recombinant *Listeria* strain in the manufacture of a medicament for eliciting an anti-tumor or anti-cancer immune response in a subject having a tumor or cancer, wherein the recombinant *Listeria* strain comprises~~ing~~ a minigene nucleic acid construct~~, said construct~~ comprising an open reading frame encoding a chimeric protein, wherein ~~said~~the chimeric protein comprises:

(a~~.~~) ~~-~~a bacterial secretion signal sequence~~, ~~;

(b~~.~~) a ubiquitin ~~(Ub)~~ protein~~, ~~; and

(c~~.~~) ~~-~~a peptide,

wherein ~~said~~the bacterial secretion signal sequence, ~~said~~the ubiquitin protein, and ~~said~~the peptide in (a~~.-~~) to (c~~.-~~) are ~~respectively~~ arranged ~~in tandem~~ from the amino-terminus to the carboxy-terminus~~, thereby enhancing an anti-tumor response in said subject~~ of the chimeric protein.

21. The use of claim 20, wherein the open reading frame encoding the chimeric protein is linked to a second open reading frame by a Shine-Dalgarno ribosome binding site nucleic acid sequence, wherein the second open reading frame encodes a second chimeric protein comprising: (a) a second bacterial secretion signal sequence; (b) a second ubiquitin protein; and (c) a second peptide, wherein the second bacterial secretion signal sequence, the

second ubiquitin protein, and the second peptide in (a) to (c) are arranged from the amino terminus to the carboxy terminus of the second chimeric protein.

~~47. The method of claim 46, wherein said *Listeria* further comprises two or more open reading frames linked by a Shine-Dalgarno ribosome binding site nucleic acid sequence.~~

~~48. The method of claim 46, wherein said *Listeria* further comprises one to four open reading frames linked by a Shine-Dalgarno ribosome binding site nucleic acid sequence between each open reading frame.~~

~~49. The method of claims 46-48, wherein said peptide comprises one or more neoepitopes.~~

~~50~~22. The ~~method of any one of claims 46-49~~use of claim 21, wherein each open reading frame ~~comprises~~ encodes a different peptide.

23. The use of any one of claims 20-22, wherein the peptide comprises one or more neoepitopes.

~~51~~24. The ~~method~~ use of any one of claims ~~46-50~~20-23, wherein ~~said~~the minigene ~~expression~~ nucleic acid construct further comprises a 5' bacterial promoter driving expression of the minigene nucleic acid construct.

~~52~~25. The ~~method~~ use of claim ~~51~~24, wherein ~~said~~the 5' bacterial promoter is an *actA* promoter, an *hly* promoter, or a *p60* promoter.

~~53~~26. The ~~method~~ use of any one of claims ~~46-52~~20-25, wherein ~~said~~the bacterial secretion signal sequence ~~encodes~~ comprises an $ActA_{100}$ signal sequence comprising the first 100 amino acids of the ActA protein signal sequence.

~~54~~27. The ~~method~~ use of any one of claims ~~46-53~~20-26, wherein ~~said~~the bacterial secretion signal sequence is a secretion signal sequence from a listeriolysin O (LLO) protein.

~~55~~28. The ~~method~~ use of any one of claims ~~46-54~~20-27, wherein ~~said~~the recombinant *Listeria* strain comprises ~~a~~ genomic mutation~~s~~ in ~~the~~ a D-alanine race~~s~~mase (*dal*) gene and ~~the~~ a D-amino acid transferase (*dat*) gene~~s~~.

~~56~~29. The ~~method~~ use of ~~any one of~~ claim~~s~~ ~~46-55~~24, wherein the recombinant *Listeria* strain further comprises a nucleic acid molecule comprising ~~first~~ an open reading frame encoding a metabolic enzyme, and wherein ~~said~~the metabolic enzyme complements an endogenous gene that is ~~mutated~~ deleted or ~~deleted~~ mutated in ~~the~~ a chromosome of ~~said~~the recombinant *Listeria* strain.

~~57. The method of claim 56, wherein said nucleic acid molecule is integrated into the *Listeria* genome.~~

~~58~~30. The ~~method~~ use of claim ~~56~~29, wherein ~~said~~the nucleic acid molecule is in a plasmid in ~~said~~the recombinant *Listeria* strain, and wherein ~~said~~the plasmid is stably maintained in ~~said~~the recombinant *Listeria* strain in the absence of antibiotic selection.

~~59~~31. The ~~method~~ use of ~~any one of claims 56-58~~claim 29 or 30, wherein ~~said~~the metabolic enzyme is an alanine racemase enzyme or a D-amino acid transferase enzyme.

~~60~~32. The ~~method~~ use of any one of claims ~~46-59~~20-31, wherein ~~said~~the minigene ~~expression~~ nucleic acid construct is integrated into the *Listeria* genome or is in an extrachromosomal plasmid in ~~said~~the recombinant *Listeria* strain.

~~61~~33. The ~~method~~ use of any one of claims ~~46-60~~20-32, wherein ~~said~~the recombinant *Listeria* strain comprises a genomic mutation in the *actA* gene.

~~62~~34. The ~~method~~ use of any one of claims ~~46-61~~20-33, wherein ~~said~~the recombinant *Listeria* strain comprises a genomic mutation in the *inlB* gene.

~~63~~35. The ~~method~~ use of any one of claims ~~46-62~~20-34, wherein ~~said~~the recombinant *Listeria* strain comprises a genomic mutation in the *prfA* gene.

~~64~~36. The ~~method~~ use of any one of claims ~~46-63~~20-35, wherein ~~said~~the recombinant ~~attenuated~~ *Listeria* strain is a *Listeria monocytogenes*.

~~65~~37. The ~~method~~ use of any one of claims ~~46-64~~20-36, ~~further comprising administration of~~ wherein the medicament is for use in combination with an independent adjuvant.

~~66~~38. The ~~method~~ use of claim ~~65~~37, wherein ~~said~~the adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSF) protein, a nucleotide molecule encoding a GM-CSF protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide.

39. The use of any one of claims 20-38, wherein the anti-tumor or anti-cancer immune response is a $CD8^+$ T cell immune response.

40. The use of any one of claims 20-39, wherein the medicament is for treating a tumor or cancer in the subject.

~~67~~41. The ~~method~~ use of any one of claims ~~46-66~~20-40, wherein ~~said~~the cancer comprises a lymphoma, a leukemia, a breast cancer, a colorectal cancer, a h~~H~~ead and neck squamous carcinoma, a renal cell carcinoma, a p~~P~~ancreatic ductal adenocarcinoma, an osteosarcoma, a gastric cancer, a non-small cell lung cancer ~~or,~~ a bone cancer, or a refractory cancer.

~~68. The method of any one of claims 46-67, wherein said cancer is a refractory cancer.~~

~~69~~42. The ~~method~~ use of claim ~~67~~41, wherein ~~said~~the lymphoma is Hodgkin's l~~L~~ymphoma or n~~N~~on-Hodgkin's l~~L~~ymphoma.

~~70. The method of claim 67, wherein said lymphoma is multiple myeloma.~~

~~71. The method of any one of claims 21-70, wherein said administration comprises at least two administrations of said recombinant attenuated *Listeria*.~~

~~72~~43. The ~~method~~ use of any one of claims ~~21-71~~40-42, wherein the medicament is for administration ~~further comprising a step of administering said recombinant attenuated *Listeria*~~ following a relapse or metastasis of ~~said~~the cancer in ~~said~~the subject.

~~73~~44. The ~~method~~ use of any one of claims ~~21-72~~40-43, wherein the medicament is for use as ~~further comprising administering~~ a booster shot.

45. The use of any one of claims 40-44, wherein the medicament delays metastatic disease, reduces lymph node size, results in progression-free survival, or increases the time to disease progression.

~~74. The method of any one of claims 21-73, wherein said immune response is a CD8^{+} T cell immune response.~~

~~75. The method of any one of claims 46-74, wherein said treating delays metastatic disease.~~

~~76. The method of any one of claims 46-75, wherein said treating reduces lymph node size.~~

~~77. The method of any one of claims 46-76, wherein said treating results in progression free survival.~~

~~78. The method of any one of claims 46-76, wherein said treating results in increase of the time to disease progression.~~

~~79~~46. Use of the recombinant *Listeria* strain of any one of claims 1-18 in the manufacture of a medicament for ~~A method of~~ suppressing or delaying formation of a tumor or cancer in a subject.

47. Use of the recombinant *Listeria* strain of any one of claims 1-18 in the manufacture of a medicament for~~, the method comprising the step of administering the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20~~ for breaking tolerance to a self-antigen in a subject.

~~80~~48. Use of the recombinant *Listeria* strain of any one of claims 1-18 in the manufacture of a medicament for~~A method of breaking tolerance to a self-antigen, the method comprising the step of administering the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20~~ for inducing cancer regression in a subject.

8149. A method of inducing cancer regression in a subject, the method comprising the step of Use of the recombinant *Listeria* strain of any one of claims 1-18 in the manufacture of a medicament foradministering the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20 for prolonging survival in a subject.

82. A method of prolonging survival in a subject, the method comprising the step of administering the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20.

83. Use of a recombinant *Listeria* for eliciting an anti-tumor or anti-cancer response in a subject having a tumor or cancer, said use comprising the step of administering said *Listeria* to said subject having said tumor or cancer, wherein said recombinant *Listeria* comprises a minigene nucleic acid construct, wherein said nucleic acid construct comprises an open reading frame encoding a chimeric protein, wherein said chimeric protein comprises:

a. a bacterial secretion signal sequence,

b. an ubiquitin (Ub) protein,

c. a peptide,

wherein said signal sequence, said ubiquitin and said peptide in a.-c. are respectively arranged in tandem from the amino-terminus to the carboxy-terminus.

84. The use of claim 83, wherein said *Listeria* further comprises two or more open reading frames linked by a Shine-Dalgarno ribosome binding site nucleic acid sequence.

85. The use of claim 83, wherein said *Listeria* further comprises one to four open reading frames linked by a Shine-Dalgarno ribosome binding site nucleic acid sequence between each open reading frame.

86. The use of claims 83-85, wherein said peptide comprises one or more neoepitopes.

87. The use of claims 83-86, wherein each open reading frame comprises a different peptide.

~~88. The use of claims 83-87, wherein said minigene construct further comprises a 5' bacterial promoter driving expression of the nucleic acid construct.~~

~~89. The use of claim 88, wherein said promoter is an *actA* promoter, an *hly* promoter, or a *p60* promoter.~~

~~90. The use of claims 83-89, wherein said bacterial secretion signal sequence encodes an $ActA_{100}$ signal sequence comprising the first 100 amino acids of the ActA protein signal sequence.~~

~~91. The use of claims 83-90, wherein said bacterial secretion signal sequence is a secretion signal sequence from listeriolysin O (LLO) protein.~~

~~92~~50. The use of any one of claims ~~83-91~~20 and 46-69, wherein ~~said~~the bacterial secretion signal sequence is a secretion signal sequence from a listeriolysin O (LLO) protein and comprises SEQ ID NO: 4, wherein the recombinant *Listeria* strain comprises ~~a~~ genomic mutations in ~~the~~ a D-alanine racemase (*dal*) gene, ~~and the~~a D-amino acid transferase (*dat*) gene~~s.~~

~~93. The use of claim 88~~, and an *actA* gene, wherein the recombinant *Listeria* strain further comprises a nucleic acid molecule~~-~~ comprising ~~first~~ an open reading frame encoding a metabolic enzyme, and wherein ~~said~~the metabolic enzyme ~~complements an endogenous gene that is deleted or mutated in the chromosome of said recombinant *Listeria* strain.~~

~~94. The use of claim 93, wherein said nucleic acid molecule is integrated into the *Listeria* genome.~~

~~95. The use of any one of claims 93, wherein said nucleic acid molecule is in a plasmid in said recombinant *Listeria* strain, and wherein said plasmid is stably maintained in said recombinant *Listeria* strain in the absence of antibiotic selection.~~

~~96. The use of claim of any one of claims 93-95, wherein said metabolic enzyme~~ is an alanine racemase enzyme or a D-amino acid transferase enzyme.

97. The use of claims 83-96, wherein said minigene construct is integrated into the *Listeria* genome or is in an extrachromosomal plasmid in said *Listeria*.

98. The use of claims 83-97, wherein said recombinant *Listeria* comprises a genomic mutation in the *actA* gene.

99. The use of claims 83-98, wherein said recombinant *Listeria* comprises a genomic mutation in the *inlB* gene.

100. The use of claims 83-99, wherein said recombinant *Listeria* comprises a genomic mutation in the *prfA* gene.

101. The use of claims 83-100, wherein said recombinant attenuated *Listeria* is a *Listeria monocytogenes*.

102. The use of claims 83-101, further comprising administration of an independent adjuvant.

103. The use of claim 102, wherein said adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSF) protein, a nucleotide molecule encoding a GM-CSF protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide.

104. The use of any one of claims 83-103, wherein said immune response is a $CD8^+$ T cell immune response.

105. The use of any one of claims 83-104, for treating a tumor or cancer in a subject.

106. The use of any one of claims 83-105, wherein said cancer comprises a lymphoma, a leukemia, a breast cancer, colorectal cancer, Head and neck squamous carcinoma, renal cell carcinoma, Pancreatic ductal adenocarcinoma, osteosarcoma, gastric cancer, non-small cell lung cancer or a bone cancer.

~~107. The use of any one of claims 83-106, wherein said cancer is a refractory cancer.~~

~~108. The use of claim 106, wherein said lymphoma is Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma.~~

~~109. The use of any one of claims 105-108, further comprising a step of administering said recombinant attenuated *Listeria* following a relapse or metastasis of said cancer in said subject.~~

~~110. The use of any one of claims 104-109, further comprising administering a booster shot.~~

~~111. The use of any one of claims 104-110, wherein said treating delays metastatic disease.~~

~~112. The use of any one of claims 104-111, wherein said treating reduces lymph node size.~~

~~113. The use of any one of claims 104-112, wherein said treating results in progression free survival.~~

~~114. The use of any one of claims 104-113, wherein said treating results in increase of the time to disease progression.~~

~~115. Use of the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20 for suppressing or delaying formation of a tumor or cancer in a subject, the use comprising the step of administering the recombinant *Listeria* or the pharmaceutical composition to the subject.~~

~~116. Use of the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20 for breaking tolerance to a self-antigen, the use comprising the step of administering the recombinant *Listeria* or the pharmaceutical composition to the subject.~~

~~117. Use of the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20 for inducing cancer regression in a subject, the use comprising the step of administering the recombinant *Listeria* or the pharmaceutical composition to the subject.~~

~~118. Use of the recombinant *Listeria* of claims 1-19 or the pharmaceutical composition of claim 20 for prolonging survival in a subject, the use comprising the step of administering the recombinant *Listeria* or the pharmaceutical composition to the subject.~~